HUREL Micro Liver Overview Webinar
Visikol's CEO Michael Johnson, Ph.D. gives an overview of Visikol's HUREL Micro Liver products and services. [...]
HUREL Models Assist in the Evaluation of Hepatoxicity
Many drug candidates fail during clinical trials and post-market withdrawal due to hepatoxicity or Drug Induced Liver Injury (DILI). [...]
HUREL Model Micro Livers and Hepatitis B
While hepatitis B infection is preventable by a well-established vaccine, the disease has proven to be [...]
HUREL Products and Services Are Now Part of Visikol
BICO has acquired HUREL micro liver technologies to offer the market's most comprehensive liver in vitro services BICO, leading [...]